Drug Information

Drug General Information
Drug ID
D0KA9L
Former ID
DNCL002744
Drug Name
AME-133v
Synonyms
Ocaratuzumab
Drug Type
Antibody
Indication Non-hodgkin's lymphoma [ICD10:C85] Phase 2 [521860], [549678]
Company
MENTRIK Biotech
Target and Pathway
Target(s) B-lymphocyte antigen CD20 Target Info [531756]
KEGG Pathway Hematopoietic cell lineage
References
Ref 521860ClinicalTrials.gov (NCT00354926) Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma. U.S. National Institutes of Health.
Ref 549678J Clin Oncol 30, 2012 (suppl, abstr 8081).
Ref 531756Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1;18(5):1395-403.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.